From Yahoo Finance: 2025-03-29 10:40:00

BTIG lowered Humacyte’s price target to $8 from $10 due to increased share count, maintaining a Buy rating post Q4 report. Analyst sees early commercial traction as evidence of Acellular Tissue Engineered Vessel’s “game-changing nature.” Published on TheFly for real-time financial news. Check out top-performing stocks on TipRanks.



Read more at Yahoo Finance: Humacyte price target lowered to $8 from $10 at BTIG